HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 1, 2011, Pages 59-68

  Lübberstedt, Marc ^a   Müller Vieira, Ursula ^b   Mayer, Manuela ^b   Biemel, Klaus M ^b   Knöspel, Fanny ^a   Knobeloch, Daniel ^a   Nüssler, Andreas K ^c   Gerlach, Jörg C ^a,d   Zeilinger, Katrin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Pharmacelsus GmbH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cytochrome P450; HepaRG; Hepatocyte characterization methods; Intrinsic clearance; P450 enzyme induction; Primary human hepatocytes

Indexed keywords

ALBUMIN; AMIODARONE; BETA NAPHTHOFLAVONE; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; GALACTOSE; GLUCOSE; LACTIC ACID; METHOTREXATE; MEVINOLIN; RIFAMPICIN; SORBITOL; TACRINE; TROGLITAZONE; UREA; VERAPAMIL;

ADULT; AGED; ARTICLE; CELL METABOLISM; CLEARANCE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; XENOBIOTIC METABOLISM;

CARCINOMA, HEPATOCELLULAR; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CLINICAL CHEMISTRY TESTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MALE; METABOLIC DETOXICATION, PHASE II; PHARMACEUTICAL PREPARATIONS;

EID: 78650773222     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.04.013     Document Type: Article

References (42)

1. Alexandre E., Viollon-Abadie C., David P., Gandillet A., Coassolo P., Heyd B., Mantion G., Wolf P., Bachellier P., Jaeck D., Richert L. Cryopreservation of adult human hepatocytes obtained from resected liver biopsies. Cryobiology 2002, 44:103-113.
2. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouët S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metabolism and Disposition 2006, 34:75-83.
3. Ballet F., Bouma M.E., Wang S.R., Amit N., Marais J., Infante R. Isolation, culture and characterization of adult human hepatocytes from surgical liver biopsies. Hepatology 1984, 4:849-854.
4. Becquemont L., Le Bot M.A., Riche C., Funck-Brentano C., Jaillon P., Beaune P. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998, 8:101-108.
5. Begue J.M., Le Bigot J.F., Guguen-Guillouzo C., Kiechel J.R., Guillouzo A. Cultured human adult hepatocytes: A new model for drug metabolism studies. Biochemical Pharmacology 1983, 32:1643-1646.
6. Benedetti M.S., Dostert P. Contribution of amine oxidases to the metabolism of xenobiotics. Drug Metabolism Reviews 1994, 26:507-535.
7. Brandon E.F., Raap C.D., Meijerman I., Beijnen J.H., Schellens J.H. An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicology and Applied Pharmacology 2003, 189:233-246.
8. Cerec V., Glaise D., Garnier D., Serban M., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007, 45:957-967.
9. Choi D.H., Shin W.G., Choi J.S. Drug interaction between oral atorvastatin and verapamil in healthy subjects: Effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. European Journal of Clinical Pharmacology 2008, 64:445-449.
10. Coon M.J., Ding X.X., Pernecky S.J., Vaz A.D. Cytochrome P450: Progress and predictions. Federation of American Societies for Experimental Biology Journal 1992, 6:669-673.
11. Donato M.T., Castell J.V. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: Focus on in vitro studies. Clinical Pharmacokinetics 2003, 42:153-178.
12. Fabre G., Julian B., Saint-Aubert B., Joyeux H., Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metabolism and Disposition 1993, 21:978-985.
13. Fraslin J.M., Kneip B., Vaulont S., Glaise D., Munnich A., Guguen-Guillouzo C. Dependence of hepatocyte-specific gene expression on cell-cell interactions in primary culture. European Molecular Biology Organisation Journal 1985, 4:2487-2491.
14. George J., Goodwin B., Liddle C., Tapner M., Farrel G.C. Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes. Journal of Laboratory and Clinical Medicine 1997, 129:638-648.
15. Gómez-Lechón M.J., Donato T., Jover R., Rodriguez C., Ponsoda X., Glaise D., Castell J.V., Guguen-Guillouzo C. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. European Journal of Biochemistry 2001, 268:1448-1459.
16. Griffin S.J., Houston J.B. Prediction of in vitro intrinsic clearance from hepatocytes: Comparison of suspensions and monolayer cultures. Drug Metabolism and Disposition 2005, 33:115-120.
17. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences 2002, 99:15655-15660.
18. Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen- Guillouzo C. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico-Biological Interactions 2007, 168:66-73.
19. Guillouzo A., Morel F., Fardel O., Meunier B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 1993, 82:209-219.
20. Hewitt N.J., Bühring K.U., Dasenbrock J., Haunschild J., Ladstetter B., Utesch D. Studies comparing in vivo: In vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metabolism and Disposition 2001, 29:1042-1050.
21. Hickman D., Wang J.P., Wang Y., Unadkat J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition 1998, 26:207-215.
22. Hynninen V.V., Olkkola K.T., Leino K., Lundgren S., Neuvonen P.J., Rane A., Valtonen M., Laine K. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundamental & Clinical Pharmacology 2007, 21:651-656.
23. Iwase M., Kurata N., Ehana R., Nishimura Y., Masamoto T., Yasuhara H. Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro. Human & Experimental Toxicology 2006, 25:715-721.
24. Jacobsen W., Kirchner G., Hallensleben K., Mancinelli L., Deters M., Hackbarth I., Benet L.Z., Sewing K.F., Christians U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metabolism and Disposition 1999, 27:173-179.
25. Jordan C.G., Rashidi M.R., Laljee H., Clarke S.E., Brown J.E., Beedham C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. Journal of Pharmacy and Pharmacology 1999, 51:411-418.
26. Jossé R., Aninat C., Glaise D., Dumont J., Fessard V., Morel F., Poul J.M., Guguen-Guillouzo C., Guillouzo A. A long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metabolism and Disposition 2008, 36:1111-1118.
27. Kannebratt K.P., Anderson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metabolism and Disposition 2008, 36:1444-1452.
28. Kannebratt K.P., Andersson T.B. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metabolism and Disposition 2008, 36:137-145.
29. Lanford R.E., Carey K.D., Estlack L.E., Smith G.C., Hay R.V. Analysis of plasma protein and lipoprotein synthesis in long-term primary cultures of baboon hepatocytes maintained in serum-free medium. In Vitro Cellular and Developmental Biology 1989, 2:174-182.
30. Lauer B., Tuschl G., Kling M., Mueller S.O. Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chemico-Biological Interactions 2009, 179:17-24.
31. Maggs J.L., Williams D., Pirmohamed M., Park B.K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. Journal of Pharmacology and Experimental Therapeutics 1995, 275:1463-1475.
32. Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metabolism and Pharmacokinetics 2006, 21:347-356.
33. Miller C.A. Expression of the human aryl hydrocarbon receptor complex in yeast. Activation of transcription by indole compounds. The Journal of Biological Chemistry 1997, 272:32824-32829.
34. Nussler A.K., Nussler N.C., Merk V., Brulport M., Schormann W., Hengstler J.G. The holy grail of hepatocyte culturing and therapeutic use. Regenerative Medicine Today 2009, 84-122. Springer, USA. M. Santin (Ed.).
35. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 1999, 27:1350-1359.
36. Olesen O.V., Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. The Journal of Clinical Pharmacology 2001, 41:823-832.
37. Pearce R.E., Lu W., Wang Y., Uetrecht J.P., Correia M.A., Leeder J.S. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2, 3-dihydroxycarbamazepine. Drug Metabolism and Disposition 2008, 36:1637-1649.
38. Roymans D., Annaert P., Van Houdt J., Weygers A., Noukens J., Sensenhauser C., Silva J., Van Looveren C., Hendrickx J., Mannens G., Meuldermans W. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metabolism and Disposition 2005, 33:1004-1016.
39. Silva J.M., Day S.H., Nicoll-Griffith D.A. Induction of cytochrome-P450 in cryopreserved rat and human hepatocytes. Chemico-Biological Interactions 1999, 121:49-63.
40. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chemical Research in Toxicology 2003, 16:679-687.
41. Tirmenstein M.A., Hu C.X., Gales T.L., Maleeff B.E., Narayanan P.K., Kurali E., Hart T.K., Thomas H.C., Schwartz L.W. Effects of troglitazone on HepG2 viability andmitochondrial function. Toxicological Sciences 2002, 69:131-138.
42. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Venkatakrishnan K., Schmider J., Harmatz J.S., Shader R.I. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmacy and Pharmacology 1998, 50:997-1004.